武汉大学人民医院湖北省人民医院

院内导航

曹德东肿瘤
医疗部副部长，主任医师，硕士生导师

A+ A-

导师介绍

姓名	曹德东
出生年月	1985年6月
单位	武汉大学人民医院肿瘤三科
所属学科	临床医学-肿瘤学
职务、职称及头衔	医疗部副部长，主任医师，硕士生导师
E-mail	caodedong123@whu.edu.cn
联系方式	027-88041911转85015
研究方向	1.放射治疗增敏策略与机制 2.肿瘤代谢与肿瘤免疫治疗 3.肿瘤循证医学
个人简介	主要从事恶性肿瘤的诊治与科研工作，主持或参与国家级研究项目5项、省市校级课题8项、院内项目2项。以Sub-I身份申请、参与及管理多项临床试验。主编医学著作《如何谈癌不色变？专家为你揭开癌症面纱》、《现代肿瘤诊疗新进展》，在《Ther Adv Med Oncol》、《Oncoimmunology》、《Clin Transl Med》等中英文杂志上发表论文40余篇，其中基础研究系列SCI论文16篇，肿瘤循证系列SCI论文17篇，肿瘤循证系列统计源论文数篇。已参与培养博士生、硕士生8名。目前正在参与培养的硕士生5名。
学术任职与荣誉	中国抗癌协会肿瘤热疗专委会头颈热疗专委会常委中国研究型医院学会精准医学与肿瘤MDT专业委员会儿童复杂肿瘤学组副组长湖北省抗癌协会淋巴瘤专业委员会委员湖北省抗癌协会肿瘤热疗专业委员会委员湖北省微循环协会会员 American Association for Cancer Research会员 Cochrane循证机构会员 BMC Cancer杂志编辑《中国医药导报》杂志编委 Frontiers in Oncology专刊编辑 Journal for ImmunoTherapy of Cancer杂志评审专家 Oncoimmunology杂志评审专家 Aging杂志评审专家 Cancer Medicine杂志评审专家 World Journal of Surgical Oncology杂志评审专家 Dove Medical Press系列杂志评审专家 Spandidos Publications系列杂志评审专家
教育履历	2004.09-2009.06郧阳医学院第二临床学院临床医学专业本科生获学士学位 2009.09-2011.06武汉大学第一临床学院肿瘤学硕士研究生获硕士学位 2011.09-2014.06华中科技大学同济医学院第一临床学院内科学博士研究生获博士学位
工作履历	2014.07-2014.10 武汉大学人民医院肿瘤三科医师 2014.11-2017.10 武汉大学人民医院肿瘤三科主治医师 2017.11-2018.01 武汉大学人民医院肿瘤三科副主任医师 2018.02-2019.07 美国 Fred Hutchinson Cancer Research Center访问学者 2019.08-2020.01 武汉大学人民医院肿瘤三科副主任医师 2020.02- 2020.04 武汉大学人民医院发热门诊、发热留观病房副主任医师 2020.05-2022.11，武汉大学人民医院肿瘤三科副主任医师 2022.04至今，武汉大学人民医院医疗部副部长 2022.11至今，武汉大学人民医院肿瘤三科主任医师，副教授
成果获奖	1.原发性肝癌发生发展的机制及其精准治疗，湖北省科学技术进步一等奖； 2. 重组人血管内皮抑素（Endostar）增加放疗敏感性的机制及临床应用探讨，湖北省科学技术进步三等奖； 3. 重组人血管内皮抑素（Endostar）增加放疗敏感性的机制及临床应用探讨，武汉市科学技术进步三等奖。
代表性论著	1. Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X. The application of nanoparticles in immunotherapy for hepatocellular carcinoma. J Control Release. 2023 Mar;355:85-108. doi: 10.1016/j.jconrel.2023.01.051. Epub 2023 Feb 2. PMID: 36708880. 2. Shen Y, Zhao N, Zhao N, Hu X, He X, Xu Y, Chen J, Chen W, Liu X, Zhou Z, Cao D, Xu X. Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers. Int J Mol Sci. 2022 Sep 16;23(18):10823. doi: 10.3390/ijms231810823. PMID: 36142734; PMCID: PMC9501226. 3. Feng J, Ren J, Li X, Zhang X, Yang Q, Wu Z, Cui L, Liao L, Gong Y, Cao D. Phagocytosis-Regulators-Based Signature to Predict the Prognosis and Chemotherapy Resistance for Breast Cancer Patients. Int J Mol Sci. 2022 Sep 7;23(18):10312. doi: 10.3390/ijms231810312. PMID: 36142251; PMCID: PMC9499262. 4. Xu H, Xu X, Wang H, Ge W, Cao D. The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020 May;149:102909. doi: 10.1016/j.critrevonc.2020.102909. Epub 2020 Feb 19. PMID: 32146284. 5. Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019 Jun 16;8(9):e1629258. doi: 10.1080/2162402X.2019.1629258. PMID: 31428527; PMCID: PMC6685508. 6. Xu H, Xu X, Ge W, Lei J, Cao D. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020 Dec 18;12:1758835920980546. doi: 10.1177/1758835920980546. PMID: 33425028; PMCID: PMC7758867. 7. D Cao, H Xu, X Xu, T Guo, W Ge. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncoimmunology, 2018, 7(11): e1507262. 8. W Ge, H Xu, Y Yan, D Cao. The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Radiation Oncology, 2018, 13(1): 155. 9. Xu H, Cao D, Zhou D, He A, Ge W, Xu X. Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis. J Oncol. 2023 Jan 13;2023:4477263. doi: 10.1155/2023/4477263. PMID: 36688004; PMCID: PMC9859691. 10. Cao D, Zheng Y, Xu H, Ge W, Xu X. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis. Sci Rep. 2019 Dec 30;9(1):20326. doi: 10.1038/s41598-019-56528-2. PMID: 31889159;PMCID: PMC6937309. 11. Zhao N, Xu H, Zhou D, Xu X, Ge W, Cao D. The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis. J Gastrointest Oncol. 2022 Aug;13(4):1772-1781. doi: 10.21037/jgo-22-683. PMID: 36092324; PMCID: PMC9459190. 12. 曹德东,徐敏,蒋振旻,等. 胸腔内注射榄香烯治疗肺癌恶性胸腔积液疗效的系统评价[J]. 现代肿瘤医学,2018,26(2):223-229. DOI:10.3969/j.issn.1672-4992.2018.02.017.
Name	Dedong Cao
Date of birth	June，1985
Department	Oncology Department，Renmin Hospital,Wuhan University.
Title	Deputy Chief Physician, Master Tutor
Email	caodedong123@@whu.edu.cn
TEL	027-88041911-85015
Research Direction	1. Strategies and mechanisms of radiotherapy 2. Tumor metabolism and tumor immunotherapy 3. Evidence Based Medicine of Cancer
Research Direction
Personal Profile	Dr. Cao is mainly engaged in the diagnosis, treatment and scientific research of malignant tumors, and has presided over or participated in 5 national research projects, 8 provincial and provincial university-level projects, and 2 hospital projects. Apply for, participate in and manage multiple clinical trials as a Sub-I. Editor-in-chief of medical book "How to Talk about Cancer Color Change? Experts reveal the veil of cancer for you ", "New Progress in Modern Cancer Diagnosis and Treatment", in Ther Adv Med Oncol ", "Oncoimmunology", "Clin Transl Med" and other Chinese and English journals published more than 40 papers, including basic research series SCI papers 16, There were 17 SCI papers in the oncology evidence-based series and several statistical source papers. Has participated in the training of 8 graduate students. Currently, 5 master students are participating in the training. By now, Dr. Cao has participanted in educating 8 masters. At present, there are 5 Masters studying with him.
Selected Publications	1. Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X. The application of nanoparticles in immunotherapy for hepatocellular carcinoma. J Control Release. 2023 Mar;355:85-108. doi: 10.1016/j.jconrel.2023.01.051. Epub 2023 Feb 2. PMID: 36708880. 2. Shen Y, Zhao N, Zhao N, Hu X, He X, Xu Y, Chen J, Chen W, Liu X, Zhou Z, Cao D, Xu X. Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers. Int J Mol Sci. 2022 Sep 16;23(18):10823. doi: 10.3390/ijms231810823. PMID: 36142734; PMCID: PMC9501226. 3. Feng J, Ren J, Li X, Zhang X, Yang Q, Wu Z, Cui L, Liao L, Gong Y, Cao D. Phagocytosis-Regulators-Based Signature to Predict the Prognosis and Chemotherapy Resistance for Breast Cancer Patients. Int J Mol Sci. 2022 Sep 7;23(18):10312. doi: 10.3390/ijms231810312. PMID: 36142251; PMCID: PMC9499262. 4. Xu H, Xu X, Wang H, Ge W, Cao D. The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020 May;149:102909. doi: 10.1016/j.critrevonc.2020.102909. Epub 2020 Feb 19. PMID: 32146284. 5. Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019 Jun 16;8(9):e1629258. doi: 10.1080/2162402X.2019.1629258. PMID: 31428527; PMCID: PMC6685508. 6. Xu H, Xu X, Ge W, Lei J, Cao D. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020 Dec 18;12:1758835920980546. doi: 10.1177/1758835920980546. PMID: 33425028; PMCID: PMC7758867. 7. D Cao, H Xu, X Xu, T Guo, W Ge. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncoimmunology, 2018, 7(11): e1507262. 8. W Ge, H Xu, Y Yan, D Cao. The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Radiation Oncology, 2018, 13(1): 155. 9. Xu H, Cao D, Zhou D, He A, Ge W, Xu X. Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis. J Oncol. 2023 Jan 13;2023:4477263. doi: 10.1155/2023/4477263. PMID: 36688004; PMCID: PMC9859691. 10. Cao D, Zheng Y, Xu H, Ge W, Xu X. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis. Sci Rep. 2019 Dec 30;9(1):20326. doi: 10.1038/s41598-019-56528-2. PMID: 31889159;PMCID: PMC6937309. 11. Zhao N, Xu H, Zhou D, Xu X, Ge W, Cao D. The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis. J Gastrointest Oncol. 2022 Aug;13(4):1772-1781. doi: 10.21037/jgo-22-683. PMID: 36092324; PMCID: PMC9459190. 12. 曹德东,徐敏,蒋振旻,等. 胸腔内注射榄香烯治疗肺癌恶性胸腔积液疗效的系统评价[J]. 现代肿瘤医学,2018,26(2):223-229. DOI:10.3969/j.issn.1672-4992.2018.02.017.